Neutrophil to lymphocyte ratio predicts cardiovascular events in people with type 2 diabetes: Post hoc analysis of the SUSTAIN 6 and PIONEER 6 cardiovascular outcomes trials.

The high NLR tertile was associated with a 74% increased risk of expanded MACE and a twofold increased risk of CV death and all-cause death (secondary outcomes) vs. the low NLR tertile (Figure S2A). Antidiabetic drug, cardiovascular disease, GLP-1 analogue, randomized trial, type 2 diabetes Keywords: antidiabetic drug; cardiovascular disease; GLP-1 analogue; randomized trial; type 2 diabetes EN antidiabetic drug cardiovascular disease GLP-1 analogue randomized trial type 2 diabetes 2398 2401 4 07/04/23 20230801 NES 230801 INTRODUCTION Inflammation plays a critical role in the pathobiology of cardiometabolic diseases.[[1]] Neutrophils participate in this inflammatory response by releasing inflammatory mediators that cause vascular wall dysfunction; lymphocytes can augment or mute inflammatory responses, depending on the subtype.[2] Studies suggest that the neutrophil to lymphocyte ratio (NLR) may more accurately predict cardiovascular (CV) events than leukocyte counts,[3] and that NLR can predict CV disease (CVD) risk and all-cause mortality in diverse populations,[2], [4], [5], [6] including people with type 2 diabetes (T2D).[7], [8], [9], [10] The SUSTAIN 6[11] and PIONEER 6[12] trials investigated CV outcomes with subcutaneous and oral semaglutide, respectively, versus placebo in people with T2D at high CV risk. [Extracted from the article]